Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...

Fintel reports that on July 18, 2025, Jefferies upgraded their outlook for Abbott Laboratories (NYSE:ABT) from Hold to Buy.

Abbott Laboratories (NYSE:ABT) now projects organic sales growth, excluding COVID-19 testing-related sales, to grow between 7 ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

Abbott Laboratories predicts COVID-19 will be endemic this winter Abbott Laboratories, which makes the popular BinaxNow COVID-19 tests, expects significantly fewer sales of its COVID-19 tests in ...

For the current quarter ending in September, Abbott expects its per-share earnings to range from $1.28 to $1.32. The company expects full-year earnings in the range of $5.10 to $5.20 per share.

Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...